Condition deep-dive · 9 min read

NAFLD / fatty liver — what the supplement evidence actually supports

Updated 2026-05-02 · Reviewed by SupplementScore editors · No sponsorships

Non-alcoholic fatty liver disease — recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD) in updated nomenclature — affects roughly a quarter of adults globally and is the supplement aisle's other favourite hunting ground after pre-diabetes. The trial evidence is narrower than the marketing suggests, but real for two specific compounds and one specific dietary intervention.

Read this first. Fatty liver is a marker that often signals broader metabolic dysfunction — insulin resistance, central adiposity, dyslipidaemia, and elevated cardiovascular risk. The most-effective intervention for NAFLD by a wide margin is 7–10% body weight loss, which produces meaningful steatosis and inflammation reduction in essentially every trial that has measured it. Supplements complement that; they do not substitute for it. Get a clinician assessment of disease stage (steatosis vs steatohepatitis vs fibrosis) before assuming the supplement layer is sufficient.

The supplements with the strongest evidence

Tier 2 evidence · NASH histology

Vitamin E (mixed tocopherols)

800 IU/day in non-diabetic adults with biopsy-confirmed NASH

The PIVENS trial established vitamin E as the most-evidenced supplement for biopsy-confirmed non-alcoholic steatohepatitis (NASH) in non-diabetic adults — improvements in steatosis, lobular inflammation, and ballooning. Effect is modest. Important caveats: trial-validated dose and population are specific (800 IU/day, non-diabetic, biopsy-confirmed NASH); high-dose vitamin E carries small but real prostate cancer signal in long-term use, so not a free choice in older men. Use under hepatology supervision; mixed-tocopherol forms preferred over alpha-only.

Tier 2 evidence · Hepatic fat reduction

Omega-3 fatty acids (high EPA/DHA)

2–4 g/day combined EPA+DHA

Multiple meta-analyses confirm modest reductions in hepatic fat fraction and serum triglycerides at 2–4 g/day. Effect on histology is smaller and less consistent than vitamin E's. Generally reasonable to include if dietary fish intake is low. Mind the AFib paradox at chronic high doses and the antiplatelet caveat with anticoagulants.

Tier 3 evidence · Liver-enzyme reduction

Berberine

500 mg, three times daily with meals

Multiple trials show ALT and AST reductions plus modest improvements in hepatic fat content in NAFLD patients with concurrent insulin resistance. Effect is mediated through the same AMPK pathway that drives berberine's glycaemic effect. Caution alongside immunosuppressants and statins (CYP3A4 + P-gp inhibition); avoid in pregnancy.

Tier 3 evidence · Hepatoprotection

Milk thistle (silymarin or Siliphos)

200–400 mg/day standardised silymarin, or Siliphos (silybin phytosome) 100–200 mg/day

Silymarin and the more-bioavailable silybin phytosome (Siliphos) have small RCT evidence for ALT/AST reduction in NAFLD. Effect size is smaller than vitamin E. Generally well tolerated. Drug-interaction concerns are limited but real for substrates of CYP2C9 and CYP3A4 at high doses.

The supplements with smaller but real evidence

Choline (or phosphatidylcholine) — choline deficiency causes a NAFLD-like picture in animal models and in human dietary studies. Repletion in deficient patients makes sense; supraphysiological dosing has not been shown to outperform.
Curcumin (bioavailable form) — modest ALT/AST reductions in some trials. Small effect size.
Resveratrol — mixed trial results; not a primary recommendation.
Coffee (3+ cups/day) — not a supplement, but worth flagging because cohort data are remarkably consistent for coffee being protective against NAFLD progression and cirrhosis.
Vitamin D3 (in deficient patients) — observational links to NAFLD severity. Trial-grade evidence is mixed; reasonable to replete deficiency.

What to skip

"Liver detox" or "liver cleanse" multi-ingredient products — typically combine sub-therapeutic doses of milk thistle, dandelion, artichoke and others. Some include compounds (kava, comfrey, certain Asian herbs) with documented hepatotoxicity case reports — the irony is real.
High-dose niacin (immediate release) — flushing aside, can cause hepatotoxicity at the gram-level doses sometimes used for lipid management.
High-dose green tea EGCG (>800 mg/day) — EFSA-flagged hepatotoxicity at high doses on empty stomach.
Ursolic acid, garcinia cambogia, kava, comfrey, chaparral, pennyroyal, kratom — case reports of liver injury; avoid.
"Detox tea" cleanses — typically senna-based with no NAFLD relevance.

The non-supplement layer that matters most

Three lifestyle inputs out-perform every supplement in the NAFLD literature: 7–10% body weight loss (the single largest histological-improvement intervention; the LEAN trial established this), Mediterranean-pattern diet, and at least 150 minutes/week of moderate aerobic activity plus resistance training. Limiting fructose-sweetened beverages and ultra-processed food has independent evidence. GLP-1 receptor agonists (semaglutide, tirzepatide) are emerging as the first reliable pharmacological intervention for NASH; the recent ESSENCE trial of semaglutide in MASH was strongly positive. Resmetirom (Rezdiffra) is the first FDA-approved drug specifically for NASH (2024).

What to track

ALT, AST, GGT (the classic liver-enzyme panel), FIB-4 score (calculated from age, AST, ALT, platelets — a non-invasive fibrosis estimator), and ideally MR-PDFF or transient elastography (FibroScan) where available for stage tracking. Body weight and waist circumference tell you whether the lifestyle layer is moving.

Practical quick-start. Lifestyle first — target 7–10% body weight loss over 6–12 months, Mediterranean dietary pattern, eliminate sugar-sweetened beverages, add aerobic + resistance training. Supplement layer: vitamin E 800 IU mixed tocopherols daily for 24 weeks if non-diabetic and NASH-confirmed (under hepatology), omega-3 2 g/day combined EPA+DHA. Reassess ALT/AST and FIB-4 at 6 months. If progressing despite these, the conversation with hepatology about prescription options (resmetirom, GLP-1 agonist) is the right next move.